JP6408219B2 - Th1特性と細胞溶解性を発現する細胞 - Google Patents

Th1特性と細胞溶解性を発現する細胞 Download PDF

Info

Publication number
JP6408219B2
JP6408219B2 JP2013526060A JP2013526060A JP6408219B2 JP 6408219 B2 JP6408219 B2 JP 6408219B2 JP 2013526060 A JP2013526060 A JP 2013526060A JP 2013526060 A JP2013526060 A JP 2013526060A JP 6408219 B2 JP6408219 B2 JP 6408219B2
Authority
JP
Japan
Prior art keywords
cells
killer
producing
activated
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013526060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013536232A (ja
JP2013536232A5 (cg-RX-API-DMAC7.html
Inventor
マイケル ハー−ノイ
マイケル ハー−ノイ
Original Assignee
イミュノバティブ セラピーズ,リミテッド
イミュノバティブ セラピーズ,リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イミュノバティブ セラピーズ,リミテッド, イミュノバティブ セラピーズ,リミテッド filed Critical イミュノバティブ セラピーズ,リミテッド
Publication of JP2013536232A publication Critical patent/JP2013536232A/ja
Publication of JP2013536232A5 publication Critical patent/JP2013536232A5/ja
Application granted granted Critical
Publication of JP6408219B2 publication Critical patent/JP6408219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
JP2013526060A 2010-08-20 2011-08-22 Th1特性と細胞溶解性を発現する細胞 Active JP6408219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US40188110P 2010-08-20 2010-08-20
US61/401,881 2010-08-20
US201161495055P 2011-06-09 2011-06-09
US61/495,055 2011-06-09
PCT/US2011/048578 WO2012024666A2 (en) 2010-08-20 2011-08-22 Cells expressing th1 characteristics and cytolytic properties

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016235386A Division JP6525946B2 (ja) 2010-08-20 2016-12-02 Th1特性と細胞溶解性を発現する細胞

Publications (3)

Publication Number Publication Date
JP2013536232A JP2013536232A (ja) 2013-09-19
JP2013536232A5 JP2013536232A5 (cg-RX-API-DMAC7.html) 2014-10-16
JP6408219B2 true JP6408219B2 (ja) 2018-10-17

Family

ID=45594250

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013526060A Active JP6408219B2 (ja) 2010-08-20 2011-08-22 Th1特性と細胞溶解性を発現する細胞
JP2016235386A Active JP6525946B2 (ja) 2010-08-20 2016-12-02 Th1特性と細胞溶解性を発現する細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016235386A Active JP6525946B2 (ja) 2010-08-20 2016-12-02 Th1特性と細胞溶解性を発現する細胞

Country Status (19)

Country Link
US (3) US20120045423A1 (cg-RX-API-DMAC7.html)
EP (1) EP2606125B1 (cg-RX-API-DMAC7.html)
JP (2) JP6408219B2 (cg-RX-API-DMAC7.html)
KR (1) KR101900807B1 (cg-RX-API-DMAC7.html)
CN (2) CN103068973A (cg-RX-API-DMAC7.html)
AU (1) AU2011291477B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013003989B1 (cg-RX-API-DMAC7.html)
CA (1) CA2808873C (cg-RX-API-DMAC7.html)
DK (1) DK2606125T3 (cg-RX-API-DMAC7.html)
ES (1) ES2660577T3 (cg-RX-API-DMAC7.html)
HU (1) HUE036094T2 (cg-RX-API-DMAC7.html)
IL (1) IL224813B (cg-RX-API-DMAC7.html)
NO (1) NO2606125T3 (cg-RX-API-DMAC7.html)
PH (1) PH12013500519B1 (cg-RX-API-DMAC7.html)
PL (1) PL2606125T3 (cg-RX-API-DMAC7.html)
PT (1) PT2606125T (cg-RX-API-DMAC7.html)
SG (2) SG10201510524TA (cg-RX-API-DMAC7.html)
TR (1) TR201802334T4 (cg-RX-API-DMAC7.html)
WO (1) WO2012024666A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012024666A2 (en) * 2010-08-20 2012-02-23 Immunovative Therapies, Ltd. Cells expressing th1 characteristics and cytolytic properties
KR101697473B1 (ko) 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP3633029A4 (en) 2017-05-26 2021-06-09 Green Cross Lab Cell Corporation METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL
JP7179986B2 (ja) 2018-11-14 2022-11-29 グリーン クロス ラボ セル コーポレーション 形質転換されたt細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法
JP7337373B2 (ja) * 2019-07-29 2023-09-04 サイアス株式会社 抗原特異的t細胞の製造方法
US11730313B2 (en) * 2021-02-24 2023-08-22 Kirsten Wilkins Slow cooker liner system with integrated dividers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030050392A1 (en) * 1998-09-22 2003-03-13 Brother Kogyo Kabushiki Kaisha Water-based ink for ink jetting and ink jet recording method
US20030194395A1 (en) * 2001-09-17 2003-10-16 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134415A1 (en) 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
ATE457349T1 (de) 2002-08-23 2010-02-15 Multhoff Gabriele Prof Dr Granzyme b als ein hsp70/hsp70 peptid-abhängige apoptoseauslöser in tumorzellen
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
US7435592B2 (en) * 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
JP2007525225A (ja) * 2004-02-26 2007-09-06 イミュノバティブ セラピーズ, リミテッド 細胞治療のためのt細胞を調製するための方法
WO2012024666A2 (en) 2010-08-20 2012-02-23 Immunovative Therapies, Ltd. Cells expressing th1 characteristics and cytolytic properties

Also Published As

Publication number Publication date
US20120045423A1 (en) 2012-02-23
US10385315B2 (en) 2019-08-20
WO2012024666A3 (en) 2012-05-18
CA2808873A1 (en) 2012-02-23
TR201802334T4 (tr) 2018-03-21
US20130196428A1 (en) 2013-08-01
SG10201510524TA (en) 2016-01-28
KR20130103485A (ko) 2013-09-23
SG187846A1 (en) 2013-03-28
EP2606125B1 (en) 2017-11-22
PH12013500519B1 (en) 2020-06-26
HUE036094T2 (hu) 2018-06-28
PH12013500519A1 (en) 2013-05-06
IL224813B (en) 2020-06-30
WO2012024666A2 (en) 2012-02-23
ES2660577T3 (es) 2018-03-23
JP2013536232A (ja) 2013-09-19
JP2017061558A (ja) 2017-03-30
EP2606125A2 (en) 2013-06-26
CN103068973A (zh) 2013-04-24
AU2011291477B2 (en) 2016-07-28
DK2606125T3 (en) 2018-03-05
BR112013003989A2 (pt) 2017-11-14
JP6525946B2 (ja) 2019-06-05
CA2808873C (en) 2020-02-18
AU2011291477A1 (en) 2013-04-04
EP2606125A4 (en) 2014-03-19
KR101900807B1 (ko) 2018-11-08
NO2606125T3 (cg-RX-API-DMAC7.html) 2018-04-21
PT2606125T (pt) 2018-02-27
PL2606125T3 (pl) 2018-05-30
CN108245673A (zh) 2018-07-06
BR112013003989B1 (pt) 2020-11-24
US20130195825A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
US10806777B2 (en) Method for allogeneic cell therapy
JP6525946B2 (ja) Th1特性と細胞溶解性を発現する細胞
HK1257638A1 (en) Cells expressing th1 characteristics and cytolytic properties
HK1184498A (en) Cells expressing th1 characteristics and cytolytic properties

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140822

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161202

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170113

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20170203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180920

R150 Certificate of patent or registration of utility model

Ref document number: 6408219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250